Page 237 - HIV/AIDS Guidelines

Appendix B, Table 6. Characteristics of CCR5 Antagonist (Last updated March 27, 2012; last
reviewed March 27, 2012)

Dosing Recommendations
Generic Name Serum/ Adverse Events
(For dosage adjustment in
(abbreviation)/ Formulation hepatic insufficiency, see Half-life Elimination (Also see Table 13)
Trade Name
Appendix B, Table 7.)
Maraviroc (MVC)/ 150-, 300-mg • 150 mg BID when given with 14–18 hrs CYP3A4 • Abdominal pain
Selzentry tablets drugs that are strong CYP3A substrate
• Cough
inhibitors (with or without CYP3A
inducers) including PIs (except • Dizziness
TPV/r)
• Musculoskeletal symptoms
• 300 mg BID when given with
• Pyrexia
NRTIs, T20, TPV/r, NVP, RAL, and
other drugs that are not strong • Rash
CYP3A inhibitors or inducers
• Upper respiratory tract infections
• 600 mg BID when given with • Hepatotoxicity which may be preceded
drugs that are CYP3A inducers, by severe rash or other signs of
including EFV, ETR, etc. (without a systemic allergic reactions
CYP3A inhibitor)
• Orthostatic hypotension especially in
Take without regard to meals patients with severe renal insufficiency

Key to Abbreviations: BID = twice daily; CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse
transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; T20 = enfuvirtide; TPV/r = tipranavir + ritonavir

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents O-12

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.